A phase I study investigating the effect of plerixafor plus pegfilgrastim in patients with multiple myeloma or lymphoproliferative disease and having poor or adequate mobilization of progenitor and hematopoietic stem cell

Trial Profile

A phase I study investigating the effect of plerixafor plus pegfilgrastim in patients with multiple myeloma or lymphoproliferative disease and having poor or adequate mobilization of progenitor and hematopoietic stem cell

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2016

At a glance

  • Drugs Plerixafor (Primary) ; Pegfilgrastim
  • Indications Stem cell mobilisation
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 12 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top